Rtl!ersible tardive dyskinesia (TO) outcomes have been rrported in long-term neuroleptic (NL)-treated patients. I" this study the course of TO outcomes was followed-up F 3 years in a population of 125 institutionalized schizophrenic patients (mean age 57.8 years) receiving continuous NL treatment. Tardive dyskinesia occurrence I1Ui severity were assessed by means of the Rockland Simpson Scale (RSS). The prevalence of TO rose from 39.2% at the first examination to 52.8% at last follow-up aamination; however, 28.6% of TO-affected patients rtCOVered and 30% improved. Significant risk factors for a persistent TO outcome result included age over 56 years, duration of illness over 30 years, and a total RSS score over 22. Cumulative NL exposure, over 3550 g of chloropromazine equivalents, was also a significant risk factor for TO. Results from this study confirm that there is the possibility of improvement and remission in an aged, long-term institutionalized population of TO patients. In this report we point out prognostic factors for positive outcome. INeuropsychopharmacology
Tardive dyskinesia (TO) has always been considered the most dramatic side effect of chronic neuroleptic (NL) treatment, mainly because of its widely assumed ir reversibility. This assumption has influenced the ap proach to long-term treatment of schizophrenia and related disorders in dyskinetic patients because of con cerns about iatrogenesis. A number of cases showing resolution or improvement of TO symptoms have been reported since the frrst fIndings about TO were pub lished in the late fIfties. The early reports focused on pa tients whose NL treatment was withdrawn (Uhr-a persistent TO outcome result included age over 56 years, duration of illness over 30 years, and a total RSS score over 22. Cumulative NL exposure, over 3550 g of chloropromazine equivalents, was also a significant risk factor for TO. Results from this study confirm that there is the possibility of improvement and remission in an aged, long-term institutionalized population of TO patients. In this report we point out prognostic factors for positive outcome. INeuropsychopharmacology 8:233-239, 1993J brand and Faurbye 1960; Paulson 1968; Crane 1973; Hershon et al. 1972; Jeste et al. 1979; Glazer et al. 1984 Glazer et al. , 1990 , whereas more recently and more frequently, new fIndings about remissions of TO symptomatology in pa tients receiving continuous NL treatment have been published (Casey 1985; 1991; Casey et al. 1986; Casey and Gardos 1990; Gardos et al. 1988; Bergen et al. 1989; Morgenstern et al. 1987; Glazer et al. 1991) .
Oata from prospective, retrospective, longitudinal, and descriptive studies reveal that in patients receiv ing long-term NL therapy, TO often has a reversible course. These data also identify some factors that seem to be associated with remission or amelioration of symp tomatology. Among the variables studied, those most frequently involved were a younger age, NL dosage at the frrst recognition of TO, length of NL treatment, and severity of illness. Recently, Glazer et al. (1991) identi fIed age and the presence of nonorofacial dyskinetic movements at frrst evaluation as predictors of persis tent TO.
The best way to correctly evaluate the risk/benefIt 0893-133X/93/$6.00 ratio of continuing NL treatment in the natural history of TO is to undertake longitudinal studies with repeated measures (Gardos and Cole 1983) , but problems may arise from population mobility. Elderly populations have been considered the most suitable for short-term longitudinal study (Hoffmann et al. 1989) . The aim of this study was to evaluate the course of TD in a population of schizophrenic patients receiv ing continuous NL treatment, so as to identify changes in severity, remissions, new cases, and their possible predictive indicators.
METHODS
Data were obtained from a population of chronic schizophrenics residing in a psychiatric hospital. Resi dents of this kind of institution are those who have decided to remain, after the passage of a 1978 law that prohibits new admissions to long-term psychiatric hospitals. For this reason, the population we observed was peculiar in that they had only two possible ways to leave their community, discharge or death.
Initially 148 patients were admitted to the study for the fIrst observation (Altamura et al. 1990 ); however, the population available for both observations, thereby fulfilling the aim of the study, was reduced to 125 pa tients (70 males and 55 females with a mean age of 57.8 years) because 23 patients died. To be included, patients had to be diagnosed as suffering from chronic schizo phrenia or a schizoaffective disorder, and to have been treated with NL drugs for at least 3 months prior to en try into the study. To establish diagnoses, charts were reviewed and the diagnoses made on the basis of clini cal presentation and course, in accordance to DSM III criteria. Exclusion criteria were concomitant or past neu rologic diseases, alcoholism, or leucolobotomy.
Patients were rated separately by two trained psy chiatrists by means of the Rockland Simpson Scale (RSS), abbreviated version for TO (Simpson et al. 1979 ).
Scores were calculated by averaging the two ratings in a conservative way (half scores were corrected to the lower digit). Raters were blind to the patients' drug his tory and current pharmacologic treatment. Clinical charts of the patients admitted to the study were reviewed for age, age in relation to diagnosis onset, and duration of illness. For a group of 60 patients, whose missing charts did not reach a cumulative period of more than 6 months, NL and anticholinergic treatments were recorded. Neuroleptic and anticholinergic drug doses were transformed into chloropromazine and ben zotropine equivalents, respectively.
Daily doses and cumulative exposure to the drugs under study were calculated. Information about drug holidays and electroconvulsive shock therapy (ECT) treatments were obtained from the same charts. A di-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 agnosis of TD was made with a minimum total score of 19 on the RSS (in employing the rating scale, 17 is the negative score) which could be reached with a score of 3 in at least one item or a score of 2 in two items in separate body areas. Patients who amassed this score in the latter way were assessed again after 3 weeks and a score defInitively assigned (only patients with at le ast one "3" score at the second evaluation with no change in daily NL dose were considered positive). Since the RSS is a very sensitive and specmc instrument for rat ing TD in comparison with other scales, and since our diagnostic criteria were conservative, we think that this way of evaluating TD, if performed by well-trained raters, can also be useful and reliable in identifying those diffuse mild signs of TO which are often the fIrst, un derevaluated signs of this disease. In this view, we think that our criteria are comparable to those of Schooler and Kane, but fItted to the rating scale used. Patients also were assessed for extrapyramidal side effects (EPS) by means of the Simpson and Angus rating scale (SARS).
Statistical Analysis
Statistical analysis was performed using analysis of vari ance (ANOV A) and the multifactor ANOV A to com pare parametric variables; cross-tabulation with the Fisher exact test for contingency tables was used to cal culate relative risks. Only evaluations of patients who were available at both observations were considered for the statistical analysis. Patients were evaluated at ad mission (time 0) and after 3 years (time 1) by the same raters (RC. and M.G.R) using the same criteria with the same concordance in ratings (correlation coeffcient > 0.90 for both observations; correlation analysis text).
RESULTS
The sample studied consisted of 125 patients, 70 males and 55 females. The TO prevalence fIgure changed from 39.2% at fIrst observation to 52.8% at last follow-up ex amination at the end of the observation period. Among males, prevalence increased from 42.9% to 51.4%, whereas among females prevalence rose from 34.5% to 54.5%; mean age was signifIcantly higher (p < 0.001) in females (61.8 years ± 9.6 SE) than in males (54.0 years 10 SE). Of the 125 patients reassessed after 3 years, 45 remained without TD (no TD in the two evaluations, called "negative TD"), 31 developed TD (TD diagnosis at second evaluation only, called "new TD"), 35 were still affected (TD diagnosis in both evaluations, called "persistent TD"), and 14 had a complete remission of TD symptomatology (TO diagnosis at fIrst evaluation only, called "remitted TO"). Although we considered all possible conditions (Ta ble 1), data analysis was oriented toward possible differ ences in remission and persistence. The mean age, du ration of illness, and age at onset of psychiatric illness were signifIcantly lower (p < 0.0000, p = 0.01, P < 0.05, respectively) in the remitted TD group, and no signifIcant sex effect was found ( Table 1) . As a conse quence of this fInding, the relative risks of developing persistent TD were studied for age and duration of ill ness. These two variables seemed to be the most repre sentative for studying the possible neuropathologic and biologic implications of drug treatment, institutionali zation, and the natural course of schizophrenia in TD outcome. From this viewpoint, however, age at onset did not give any additional information. The relative risk of developing persistent TD for patients aged more than 56 years (the median value of the variable consid ered in the entire population) at time 0, was 9.1 (p < 0.005 two-tailed Fisher's exact test). The relative risk of developing persistent TD for patients with a duration of ill ness of more than 30 years (median value) was 11.5 (p < 0.005).
Considering the SARS total scores, the risk of de veloping persistent TD for patients with a score higher than 22 at fIrst evaluation (time 0) was 5.5 times higher (p < 0.05) than in patients with a lower score. Among patients with persistent TD, total scores remained un changed in 7, were lower in 15, and higher in 13 com pared to basal evaluation. Among these patients, the improved group had a lower mean age and duration of illness than the unchanged and worsened groups (Ta ble 2). During the 3 years of collection, the relative risk for developing TD in patients aged over 56 years var ied from 2.3 (time 0) to 3.8 (time 1) with a new higher signifIcance (p < 0.0001, Fisher's exact two-tailed test). At fIrst evaluation, EPS were found in 12.8% of the to tal sample. The highest rate was found in the negative TD group (22.2%), followed by a rate about one-half as high (11.4%) in the persistent TD group. Extrapy ramidal side effects were present among 7.1 % of remit ting patients and 3.2% of new patients. At the second evaluation, EPS were present in 11.2% of all patients, with rates of 20%,8.6%, 7.1%, and 3.2%, respectively (following the same outcome order).
Total EPS scores were not correlated to total TD scores in either of the two evaluations (correlation analy sis) nor was the presence of EPS at fIrst observation re lated to outcome at 3 years (cross-tabulation, Fisher's exact test). In the group of patients whose pharmaco-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 logic history was collected, 33.3% were affected by per sistent TD, 11.7% by remitting TD; 28.3% were new cases, and 26.7% were still not affected. A total of2S.9% of the originally TD-affected patients recovered (Table  1) . No signifIcant diff erences were found in the vari ables considered between this group and the general sample. No SignifIcant difference in mean daily NL doses was found between groups and between times for each group. No difference in mean cumulative an ticholinergic doses between groups and between two observations was found (5699.36 mg benzotropine equivalents at baseline and 5748.05 at second evalua tion). No difference was found between outcome groups in history of anticholinergic treatments, before the frrst observation or in the period between the two obser vations.
Duration of NL treatment ranged from 8 to 16 years in seven patients, from 17 to 24 years in 17 patients, from 25 to 32 years in 32 patients, and from 33 to 40 years in 4 patients. A statistically signifIcant diff erence was found in mean treatment duration between the per sistent and remitting groups (p = 0.05) ( Table 1) .
Mean cumulative doses of NL drugs for patients with persistent TD were higher than in patients with remitting TD, but did not reach statistical signifIcance (Table 1) , and relative risk, calculated for a cumulative NL dose higher than 3550 g, had a result of 9. No statisti cally signifIcant diff erence was found between groups relative to percentages of patients with increased, un changed, or decreased absolute daily doses (Table 3) .
Considering the presence of TD in our population at second the evaluation, a signifIcant diff erence (p < 0.01) in mean cumulative doses (in grams) of NLs was found between affected (4257.5 ± 312 SE) and nonaffected patients (3078 ± 318 SE). This result was affected by duration of treatment, as shown by the MANOV A test in which the same variables covariated by duration of treatment and were different at p = 0.05.
Relative risk for occurrence of TD calculated on a "cut off" value (median value) of mean cumulative NL dose (3550 g) was 3.7 (p < 0.05).
In patients with persistent TD, nine presented with reduction (absolute decrease of scale score), six with worsening of symptomatology (absolute increase of score), and fIve were unchanged (no change in score). Among these patients, the improved group had a lower mean cumulative dose of NL drugs than the unchanged group, and the latter group's variables were lower than the worsened patients (Table 2) . No statistically signifr cant difference was found in daily doses between im proved, unchanged, and worsened patients (ANOVA) and no correlation was found between change in daily doses and change in total TD scores (regression analy sis). Mean daily doses did not differ signifIcantly in these groups at time 0 and time 1. No diff erence was
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DISCUSSION
The occurrence of TO places signifIcant weight on the pharmacologic management of schizophrenia. For this reason, reports on the short-, medium-, and long-term outcome of TO have become more and more frequent in the international literature . Recent observations point out that populations of aged patients are the most suit able for short-term studies on TO (Hoffmann et al. 1989 ).
Because of its clinical and demographic character istics, our population seemed to be particularly well suited for studying the course of TO. In fact, the diag noses were homogeneous, the population lacked mobil ity, and institutionalization exposed all patients to the same extrapharmacologic variables (i.e., socio-rehabil itative treatments as well as the institutionalization effects themselves). Further pharmacologic treatment was completely recordable for a large and representa tive subgroup.
The prevalence of TO increased from the time of the frrst evaluation. This is almost certainly an effect of increasing age, but could also be due to the continued administration of NL drugs, or both. This last hypoth esis seems to be the more probable. A clear influence of the duration of treatment, which could be consid ered a time-dependent toxicologic effect, was found (see MANOVA results), but this does not completely ac count for the effect of diff erences in cumulative doses of NL drugs, which is a direct measure of total quan titative exposure. In fact, after statistical analysis of the duration of treatment as a covariate, its significance is reduced, but not lost. If we consider this finding along with that of no significant difference found in NL cu mulative doses at the frrst evaluation (Altamura et al. 1990 ) (diff erence was at the p = 0.08 level) 3 years ago, we can hypothesize that a threshold of quantitative ex posure to NL was overcome in several patients during these 3 years, with the concomitant weight of a time dependent variable (increased duration of treatment to gether with aging of neurologic substratum).
After 3 years, the prevalence value was 20% higher in females (versus a 7.5% increase in males). This re sult is consistent with that of Woerner et al. (1991) who found a similar pattern of prevalence and prevalence diff erences according to sex, with a greater prevalence among older females. Considering that a significant number of these patients were postmenopausal, these data seem to confrrm the hypothesis of a protective role of estrogens suggested by some of the literature (Glazer et al. 1985; Smith et al. 1978) . Risk factors found for a poor outcome appear to be the same as those for TD occurrence. Age, duration of illness, and duration of treatment were signifIcantly higher in the persistent TD group than in the remitting group. A direct implication of this result may be that more factors depending on the neurologic substratum (aging), toxicological charge (duration of treatment), and duration of psychiatric illness (but this could also be due to a "tracking" effect of the variable duration of treatment) come together, not only to determine TD oc currence, but also its outcome. From this viewpoint, a possible genetic predisposition to TD would not be come phenotypically evident if some complex condi tions were not realized and maintained. We think it is also worth noting that in our descriptive analysis re garding persistent TD courses (statistical analysis was not performed due to the small number in each group) the same variables were found to be lower in patients with an improved course.
In any case, data from this study are subject to the possibility that TD can have an "intermittent" course with remissions and exacerbations, as was found by 
